Citation Impact
Citing Papers
Human Immunodeficiency Virus Type 2 (HIV-2)/HIV-1 Envelope Chimeras Detect High Titers of Broadly Reactive HIV-1 V3-Specific Antibodies in Human Plasma
2008
Maturation-Dependent HIV-1 Surface Protein Redistribution Revealed by Fluorescence Nanoscopy
2012 StandoutScienceNobel
Expression of HIV-1 Envelope Glycoproteins by Semliki Forest Virus Vectors
1993
The Yellow Fever Virus Vaccine Induces a Broad and Polyfunctional Human Memory CD8+ T Cell Response
2009 StandoutNobel
Selective Expansion of HIV-1 Envelope Glycoprotein-Specific B Cell Subsets Recognizing Distinct Structural Elements Following Immunization
2009
Multistate and functional protein design using RoseTTAFold sequence space diffusion
2024 StandoutNobel
The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates
1996 Standout
High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination
2009
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Immunization with Tween-ether-treated SIV adsorbed onto aluminum hydroxide protects monkeys against experimental SIV infection
1992
Mechanisms of Protection Induced by Attenuated Simian Immunodeficiency Virus
2002
Changes in glycoconjugate expression during early chick embryo development: A lectin‐binding study
1991
Emerging cephalosporins
2007
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
1998 StandoutNature
International Collaboration Comparing Neutralization and Binding Assays for Monoclonal Antibodies to Simian Immunodeficiency Virus
1993
Human Studies in the Development of Human Immunodeficiency Virus Vaccines
1995
Hepatitis B virus infection
2009 Standout
Structure of Dengue Virus
2002 Standout
Hepatitis C Virus Continuously Escapes From Neutralizing Antibody and T-Cell Responses During Chronic Infection In Vivo
2006 StandoutNobel
Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys
1991 Nature
Core Structure of gp41 from the HIV Envelope Glycoprotein
1997 Standout
Human Antibodies from Combinatorial Libraries
1994
Hepatitis B vaccines
2003
B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
2008 Standout
The Science of Antibiotic Discovery
2020 Standout
Epithelial–mesenchymal transitions in tumour progression
2002 Standout
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein
2002 StandoutNature
DC-SIGN, a Dendritic Cell–Specific HIV-1-Binding Protein that Enhances trans-Infection of T Cells
2000 Standout
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Tet-On Systems For Doxycycline-inducible Gene Expression
2016
Pre-eclampsia
2005 Standout
Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies
2016
Stages of embryonic development of the zebrafish
1995 Standout
Evidence for partial epithelial‐to‐mesenchymal transition (pEMT) and recruitment of motile blastoderm edge cells during avian epiboly
2011
Allo-immunization elicits CD8+ T cell-derived chemokines, HIV suppressor factors and resistance to HIV infection in women
1999
Multi-targeting by monotherapeutic antibacterials
2006
Challenges for structure-based HIV vaccine design
2009
EMT: 2016
2016 Standout
Restoring function in exhausted CD8 T cells during chronic viral infection
2005 StandoutNatureNobel
HIV as the cause of AIDS
1996 StandoutNobel
Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions
2003
A conformational transition at the N terminus of the prion protein features in formation of the scrapie isoform 1 1Edited by M. Yaniv
1997 StandoutNobel
The Role of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins in Virus Infection
1995
Synthetic glycopeptides and glycoproteins as tools for biology
2004 StandoutNobel
Heterologous Epitope-Scaffold Prime∶Boosting Immuno-Focuses B Cell Responses to the HIV-1 gp41 2F5 Neutralization Determinant
2011 StandoutNobel
Changing Virus‐Host Interactions in the Course of HIV‐1 Infection
1994
Comparison of serum antibody reactivities to a conformational and to linear antigenic sites in the external envelope glycoprotein of simian immunodeficiency virus (SIVmac) induced by infection and vaccination
1993
Virus-like particles: Designing an effective AIDS vaccine
2006
SARS-CoV-2 vaccines in development
2020 StandoutNature
Time-tagged ticker tapes for intracellular recordings
2023 StandoutNobel
Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures
2013 Standout
Effect of heterosexual intercourse on mucosal alloimmunisation and resistance to HIV-1 infection
2004
Circumventing tolerance to generate autologous monoclonal antibodies to the prion protein.
1996 StandoutNobel
Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure.
1995
Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
1996
CC CKR5: A RANTES, MIP-1α, MIP-1β Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1
1996 StandoutScience
Identification of Highly Attenuated Mutants of Simian Immunodeficiency Virus
1998
Flying Under the Radar: The Immunobiology of Hepatitis C
2006 StandoutNobel
Early protection against pathogenic virus infection at a mucosal challenge site after vaccination with attenuated simian immunodeficiency virus
2004 StandoutNobel
CD81 Is Required for Hepatitis C Virus Glycoprotein-Mediated Viral Infection
2004 StandoutNobel
Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors
2013 StandoutScienceNobel
Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1
1994
A Comprehensive Panel of Near-Full-Length Clones and Reference Sequences for Non-Subtype B Isolates of Human Immunodeficiency Virus Type 1
1998 StandoutNobel
Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera
1995
Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients
2020
Memory CD8 T-Cell Differentiation during Viral Infection
2004
Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients
1996 StandoutNobel
Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge.
1992
Low CD8 T-Cell Proliferative Potential and High Viral Load Limit the Effectiveness of Therapeutic Vaccination
2005
Acidic fibroblast growth factor is a modulator of epithelial plasticity in a rat bladder carcinoma cell line.
1990
Diverse Hepatitis C Virus Glycoproteins Mediate Viral Infection in a CD81-Dependent Manner
2004 StandoutNobel
Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine.
1992
Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization
1994
Alphavirus-based expression vectors: strategies and applications.
1996 StandoutNobel
Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains
1993
Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding
1995
Change in tropism upon immune escape by human immunodeficiency virus
1995
CD4-Induced Conformational Changes in the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein: Consequences for Virus Entry and Neutralization
1998
The biology , function , and biomedical applications of exosomes
2020 StandoutScience
Effects of Charge on Antibody Tissue Distribution and Pharmacokinetics
2010
Vigorous HIV-1-Specific CD4 + T Cell Responses Associated with Control of Viremia
1997 StandoutScience
Protective Effects of a Live Attenuated SIV Vaccine with a Deletion in the nef Gene
1992 Science
Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans
1993
Antigenic Variation within the CD4 Binding Site of Human Immunodeficiency Virus Type 1 gp120: Effects on Chemokine Receptor Utilization
2001
Analysis of the interaction of the human immunodeficiency virus type 1 gp120 envelope glycoprotein with the gp41 transmembrane glycoprotein
1997
Growth of Pseudotypes of Vesicular Stomatitis Virus with N-Tropic Murine Leukemia Virus Coats in Cells Resistant to N-Tropic Viruses
1973 StandoutNobel
Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge
1994
Rapid Infection of Oral Mucosal-Associated Lymphoid Tissue with Simian Immunodeficiency Virus
1999 StandoutScienceNobel
Imaging the glycome
2008 StandoutNobel
Ribonucleic Acud Polymerase in Virions of Newcastle Disease Virus: Comparison with the Vesicular Stomatitis Virus Polymerase
1971 StandoutNobel
Hepatitis C Virus Glycoproteins Interact with DC-SIGN and DC-SIGNR
2003 StandoutNobel
The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens
1998 StandoutScience
Design of a hyperstable 60-subunit protein icosahedron
2016 StandoutNatureNobel
Cutting Edge: Increased NK Cell Activity in HIV-1-Exposed but Uninfected Vietnamese Intravascular Drug Users
2003 StandoutNobel
The Trojan exosome hypothesis
2003
Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies
1994
A fate map of the epiblast of the early chick embryo
1994
Characterization and Epitope Mapping of Neutralizing Monoclonal Antibodies Produced by Immunization with Oligomeric Simian Immunodeficiency Virus Envelope Protein
2000
Immunological Response to Parenteral Vaccination with Recombinant Hepatitis B Virus Surface Antigen Virus-Like Particles Expressing Helicobacter pylori KatA Epitopes in a Murine H. pylori Challenge Model
2011
Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses
2006 StandoutNobel
Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer.
1995
Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines
1994
Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.
1992 Standout
Enhancement of human immunodeficiency virus type 1 envelope-mediated fusion by a CD4-gp120 complex-specific monoclonal antibody
1997
Differential N-Linked Glycosylation of Human Immunodeficiency Virus and Ebola Virus Envelope Glycoproteins Modulates Interactions with DC-SIGN and DC-SIGNR
2002 StandoutNobel
Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection
1993
Works of Mark Page being referenced
Early Potent Protection against Heterologous SIVsmE660 Challenge Following Live Attenuated SIV Vaccination in Mauritian Cynomolgus Macaques
2011
Autoantibodies to myelin basic protein are not present in the serum and CSF of MS patients
2009
Preliminary report: protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine
1990
Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers
2002
Optimization of the doxycycline-dependent simian immunodeficiency virus through in vitro evolution
2008
Studies on the immunogenicity of chinese hamster ovary cell-derived recombinant gp120 (HIV-1IIIB)
1991
Anti-MRSA β-lactams in development
2006
Restriction of serum antibody reactivity to the V3 neutralizing domain of HIV gp120 with progression to AIDS
1992
Characterization of the T‐ and B‐cell immune response to a new recombinant pre‐S1, pre‐S2 and SHBs antigen containing hepatitis B vaccine (Hepagene™); evidence for superior anti‐SHBs antibody induction in responder mice
1998
A Novel, Recombinant Triple Antigen Hepatitis B Vaccine (Hepacare<sup>®</sup>)
2001
Passive Immunization of Cynomolgus Macaques with Immune Sera or a Pool of Neutralizing Monoclonal Antibodies Failed to Protect Against Challenge with SIVmac251
1994
Vaccine Studies With the 32 H Reisolate of SIV mac251 : An Overview
1992
T-cell and antibody response characterisation of a new recombinant pre-S1, pre-S2 and SHBs antigen-containing hepatitis B vaccine; demonstration of superior anti-SHBs antibody induction in responder mice
1999
IgG Purification
1998
A Sensitive Cell-Based Assay to Measure the Doxycycline Concentration in Biological Samples
2009
Developmental patterning of the carbohydrate antigen FC10.2 during early embryogenesis in the chick
1990
Changing patterns of cytokeratins and vimentin in the early chick embryo
1989
Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120
1993
Immunisation of macaques with SIV env recombinants: Specificity of T cell and antibody responses and evaluation of protective efficacy
1993
Conditionally-live attenuated SIV upregulates global T effector memory cell frequency under replication permissive conditions
2013
The production and purification of PCR-derived recombinant simian immunodeficiency virus p27 gag protein; its use in detecting serological and T-cell responses in macaques
1990
International Biological Reference Preparations for Epidemic Infectious Diseases
2019